Special Issue

Personalized Management in Psoriasis and Atopic Dermatitis

Message from the Guest Editors

The development of a multitude of biological drugs and small molecules (e.g., JAK inhibitors) has led to a paradigm shift in the treatment of inflammatory skin diseases. These drugs are changing the lives of millions of dermatological patients around the world, and they are also helping clinicians to better understand the pathophysiology of several immune-mediated cutaneous diseases, including psoriasis, atopic dermatitis, chronic urticaria, and hidradenitis suppurativa; however, data are still limited on the place in therapy of different drugs in each subpopulation of patients, according to comorbidities, disease severity, and previous exposure to other systemic drugs. Furthermore, the search for biomarkers that might help with classification and therapy selection is still ongoing. In this Special Issue, we will focus on new drugs for the treatment of psoriasis and atopic dermatitis, with a particular interest in real-world experiences, with the aim to explore possible tailor-made treatments for each patient.

Guest Editors

Dr. Mario Valenti

- 1. Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy 2. Department of Biomedical Sciences, Humanitas University, Milan, Italy
- Prof. Dr. Antonio Costanzo
- 1. Dermatology Unit, Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy
- Humanitas Clinical and Research Center, Scientific Institute for Research, Hospitalization and Healthcare, 20089 Rozzano, Italy

Deadline for manuscript submissions

closed (20 March 2025)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/179114

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpl.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

